RESUMEN
A series of 180 vinblastine 20' amides were prepared in three steps from commercially available starting materials, systematically exploring a typically inaccessible site in the molecule enlisting a powerful functionalization strategy. Clear structure-activity relationships and a structural model were developed in the studies which provided many such 20' amides that exhibit substantial and some even remarkable enhancements in potency, many that exhibit further improvements in activity against a Pgp overexpressing resistant cancer cell line, and an important subset of the vinblastine analogues that display little or no differential in activity against a matched pair of vinblastine sensitive and resistant (Pgp overexpressing) cell lines. The improvements in potency directly correlated with target tubulin binding affinity, and the reduction in differential functional activity against the sensitive and Pgp overexpressing resistant cell lines was found to correlate directly with an impact on Pgp-derived efflux.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos/química , Antineoplásicos/farmacología , Resistencia a Antineoplásicos , Neoplasias/tratamiento farmacológico , Vinblastina/análogos & derivados , Vinblastina/farmacología , Amidas/síntesis química , Amidas/química , Amidas/farmacología , Animales , Antineoplásicos/síntesis química , Línea Celular Tumoral , Resistencia a Múltiples Medicamentos , Humanos , Neoplasias/metabolismo , Relación Estructura-Actividad , Tubulina (Proteína)/metabolismo , Moduladores de Tubulina/síntesis química , Moduladores de Tubulina/química , Moduladores de Tubulina/farmacología , Vinblastina/síntesis químicaRESUMEN
A key series of vinblastine analogs 7-13, which contain modifications to the C20' ethyl group, was prepared with use of two distinct synthetic approaches that provide modifications of the C20' side chain containing linear and cyclized alkyl groups or added functionalized substituents. Their examination revealed the unique nature of the improved properties of the synthetic vinblastine 6, offers insights into the origins of its increased tubulin binding affinity and 10-fold improved cell growth inhibition potency, and served to probe a small hydrophobic pocket anchoring the binding of vinblastine with tubulin. Especially noteworthy were the trends observed with substitution of the terminal carbon of the ethyl group that, with the exception of 9 (R=F vs H, equipotent), led to remarkably substantial reductions in activity (>10-fold): R=F (equipotent with H)>N3, CN (10-fold)>Me (50-fold)>Et (100-fold)>OH (inactive). This is in sharp contrast to the maintained (7) or enhanced activity (6) observed with its incorporation into a cyclic C20'/C15'-fused six-membered ring.
Asunto(s)
Antineoplásicos/química , Vinblastina/análogos & derivados , Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Sitios de Unión , Cristalografía por Rayos X , Células HCT116 , Humanos , Simulación de Dinámica Molecular , Unión Proteica/efectos de los fármacos , Relación Estructura-Actividad , Tubulina (Proteína)/química , Tubulina (Proteína)/metabolismo , Vinblastina/síntesis química , Vinblastina/farmacologíaRESUMEN
The continued proliferation of malaria throughout temperate and tropical regions of the world has promoted a push for more efficacious treatments to combat the disease. Unfortunately, more recent remedies such as artemisinin combination therapies have been rendered less effective due to developing parasite resistance, and new drugs are required that target the parasite in the liver to support the disease elimination efforts. Research was initiated to revisit antimalarials developed in the 1940s and 1960s that were deemed unsuitable for use as therapeutic agents as a result of poor understanding of both physicochemical properties and parasitology. Structure-activity and structure-property relationship studies were conducted to generate a set of compounds with the general 6-chloro-7-methoxy-2-methyl-4(1H)-quinolone scaffold which were substituted at the 3-position with a variety of phenyl moieties possessing various properties. Extensive physicochemical evaluation of the quinolone series was carried out to downselect the most promising 4(1H)-quinolones, 7, 62, 66, and 67, which possessed low-nanomolar EC50 values against W2 and TM90-C2B as well as improved microsomal stability. Additionally, in vivo Thompson test results using Plasmodium berghei in mice showed that these 4(1H)-quinolones were efficacious for the reduction of parasitemia at >99% after 6 days.
Asunto(s)
Antimaláricos/síntesis química , Plasmodium/efectos de los fármacos , Quinolonas/síntesis química , Animales , Antimaláricos/química , Antimaláricos/farmacología , Humanos , Concentración 50 Inhibidora , Malaria/tratamiento farmacológico , Ratones , Microsomas Hepáticos/metabolismo , Parasitemia/tratamiento farmacológico , Plasmodium berghei , Quinolonas/química , Quinolonas/farmacología , Relación Estructura-ActividadRESUMEN
Malaria kills approximately 1 million people a year, mainly in sub-Saharan Africa. Essential steps in the life cycle of the parasite are the development of gametocytes, as well as the formation of oocysts and sporozoites, in the Anopheles mosquito vector. Preventing transmission of malaria through the mosquito is necessary for the control of the disease; nevertheless, the vast majority of drugs in use act primarily against the blood stages. The study described herein focuses on the assessment of the transmission-blocking activities of potent antierythrocytic stage agents derived from the 4(1H)-quinolone scaffold. In particular, three 3-alkyl- or 3-phenyl-4(1H)-quinolones (P4Qs), one 7-(2-phenoxyethoxy)-4(1H)-quinolone (PEQ), and one 1,2,3,4-tetrahydroacridin-9(10H)-one (THA) were assessed for their transmission-blocking activity against the mosquito stages of the human malaria parasite (Plasmodium falciparum) and the rodent parasite (P. berghei). Results showed that all of the experimental compounds reduced or prevented the exflagellation of male gametocytes and, more importantly, prevented parasite transmission to the mosquito vector. Additionally, treatment with ICI 56,780 reduced the number of sporozoites that reached the Anopheles salivary glands. These findings suggest that 4(1H)-quinolones, which have activity against the blood stages, can also prevent the transmission of Plasmodium to the mosquito and, hence, are potentially important drug candidates to eradicate malaria.
Asunto(s)
Acridinas/farmacología , Anopheles/efectos de los fármacos , Antimaláricos/farmacología , Estadios del Ciclo de Vida/efectos de los fármacos , Malaria Falciparum/prevención & control , Malaria/prevención & control , Quinolonas/farmacología , Acridinas/síntesis química , Animales , Anopheles/parasitología , Antimaláricos/síntesis química , Femenino , Humanos , Insectos Vectores , Estadios del Ciclo de Vida/fisiología , Malaria/parasitología , Malaria/transmisión , Malaria Falciparum/parasitología , Malaria Falciparum/transmisión , Masculino , Ratones , Pruebas de Sensibilidad Parasitaria , Plasmodium berghei/efectos de los fármacos , Plasmodium berghei/crecimiento & desarrollo , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/crecimiento & desarrollo , Quinolonas/síntesis química , Glándulas Salivales/efectos de los fármacos , Glándulas Salivales/parasitología , Relación Estructura-ActividadRESUMEN
With the exception of primaquine, tafenoquine, and atovaquone, there are very few antimalarials that target liver stage parasites. In this study, a transgenic Plasmodium berghei parasite (1052Cl1; PbGFP-Luc(con)) that expresses luciferase was used to assess the anti-liver stage parasite activity of ICI 56,780, a 7-(2-phenoxyethoxy)-4(1H)-quinolone (PEQ), as well as two 3-phenyl-4(1H)-quinolones (P4Q), P4Q-146 and P4Q-158, by using bioluminescent imaging (BLI). Results showed that all of the compounds were active against liver stage parasites; however, ICI 56,780 and P4Q-158 were the most active, with low nanomolar activity in vitro and causal prophylactic activity in vivo. This potent activity makes these compounds ideal candidates for advancement as novel antimalarials.
Asunto(s)
Antimaláricos/síntesis química , Antimaláricos/farmacología , Malaria/tratamiento farmacológico , Plasmodium berghei/efectos de los fármacos , Quinolonas/síntesis química , Quinolonas/farmacología , Esporozoítos/efectos de los fármacos , Animales , Femenino , Genes Reporteros , Células Hep G2 , Hepatocitos/efectos de los fármacos , Hepatocitos/parasitología , Humanos , Concentración 50 Inhibidora , Cinética , Hígado/efectos de los fármacos , Hígado/parasitología , Luciferasas , Malaria/parasitología , Ratones , Ratones Endogámicos BALB C , Organismos Modificados Genéticamente , Plasmodium berghei/genética , Plasmodium berghei/crecimiento & desarrollo , Esporozoítos/crecimiento & desarrolloRESUMEN
ICI 56,780 (5) displayed causal prophylactic and blood schizonticidal activity (ED50=0.05 mg/kg) in rodent malaria models but produced rapid acquisition of parasitological resistance in P. berghei infected mice. Herein we describe the synthesis of analogues of 5 with EC50 as low as 0.15 nM against multidrug resistant P. falciparum. Optimal activity with low cross-resistance indexes (RI) to atovaquone was achieved by introducing ortho-substituted aryl moieties at the 3-position of the 7-(2-phenoxyethoxy)-4(1H)-quinolone core.
Asunto(s)
Antimaláricos/síntesis química , Quinolonas/síntesis química , Animales , Antimaláricos/química , Antimaláricos/farmacología , Atovacuona/farmacología , Línea Celular , Resistencia a Medicamentos , Ratones , Plasmodium falciparum/efectos de los fármacos , Quinolonas/química , Quinolonas/farmacología , Relación Estructura-ActividadRESUMEN
Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC(50) < 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.
Asunto(s)
Acridinas/síntesis química , Antimaláricos/síntesis química , Acridinas/química , Acridinas/farmacología , Animales , Antimaláricos/química , Antimaláricos/farmacología , Línea Celular , Resistencia a Medicamentos , Eritrocitos/efectos de los fármacos , Eritrocitos/parasitología , Humanos , Técnicas In Vitro , Ratones , Microsomas Hepáticos/metabolismo , Plasmodium falciparum/efectos de los fármacos , Solubilidad , Relación Estructura-ActividadRESUMEN
A divergent route was developed to access 3-iodo- and 6-chloro-3-iodo-4(1H)-quinolones for further elaboration via mono and/or sequential Suzuki-Miyaura cross-coupling to generate novel and medicinally important 4(1H)-quinolones. Copper- and palladium-catalyzed cyanations were used to functionalize the 4-quinolone core further.
Asunto(s)
4-Quinolonas/química , Cobre/química , Reactivos de Enlaces Cruzados/química , Paladio/química , Catálisis , Estructura MolecularRESUMEN
Since the 1940s endochin and analogues thereof were known to be causal prophylactic and potent erythrocytic stage agents in avian models. Preliminary screening in a current in vitro assay identified several 4(1H)-quinolones with nanomolar EC(50) against erythrocytic stages of multidrug resistant W2 and TM90-C2B isolates of Plasmodium falciparum. Follow-up structure-activity relationship (SAR) studies on 4(1H)-quinolone analogues identified several key features for biological activity. Nevertheless, structure-property relationship (SPR) studies conducted in parallel revealed that 4(1H)-quinolone analogues are limited by poor solubilities and rapid microsomal degradations. To improve the overall efficacy, multiple 4(1H)-quinolone series with varying substituents on the benzenoid quinolone ring and/or the 3-position were synthesized and tested for in vitro antimalarial activity. Several structurally diverse 6-chloro-2-methyl-7-methoxy-4(1H)-quinolones with EC(50) in the low nanomolar range against the clinically relevant isolates W2 and TM90-C2B were identified with improved physicochemical properties while maintaining little to no cross-resistance with atovaquone.